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BDNF signaling via its transmembrane receptor TrkB has an important role in neuronal survival, differentiation, and synaptic plasticity.
Remarkably, BDNF is capable of modulating its own expression levels in neurons, forming a transcriptional positive feedback loop. In the
current study, we have investigated this phenomenon in primary cultures of rat cortical neurons using overexpression of dominant-
negative forms of several transcription factors, including CREB, ATF2, C/EBP, USF, and NFAT. We show that CREB family transcription
factors, together with the coactivator CBP/p300, but not the CRTC family, are the main regulators of rat BDNF gene expression after TrkB
signaling. CREB family transcription factors are required for the early induction of all the major BDNF transcripts, whereas CREB itself
directly binds only to BDNF promoter IV, is phosphorylated in response to BDNF-TrkB signaling, and activates transcription from BDNF
promoter IV by recruiting CBP. Our complementary reporter assays with BDNF promoter constructs indicate that the regulation of BDNF
by CREB family after BDNF-TrkB signaling is generally conserved between rat and human. However, we demonstrate that a noncon-
served functional cAMP-responsive element in BDNF promoter IXa in humans renders the human promoter responsive to BDNF-TrkB-
CREB signaling, whereas the rat ortholog is unresponsive. Finally, we show that extensive BDNF transcriptional autoregulation,
encompassing all major BDNF transcripts, occurs also in vivo in the adult rat hippocampus during BDNF-induced LTP. Collectively, these
results improve the understanding of the intricate mechanism of BDNF transcriptional autoregulation.
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Introduction
BDNF is a widely expressed neurotrophin in the CNS that has
been described to promote the survival and differentiation of
neurons and induce neurite outgrowth in the development of the
brain (Bibel and Barde, 2000; Huang and Reichardt, 2001; Park
and Poo, 2013). In the adult brain, the main function of BDNF is
to enhance synaptic transmission, facilitate synaptic plasticity,
and promote synaptic growth (Bramham and Messaoudi, 2005;
Minichiello, 2009; Lu et al., 2013, 2014; Park and Poo, 2013). For
example, BDNF signaling is important for synaptic consolidation
(Wibrand et al., 2006; Panja et al., 2014) and memory consolida-
tion (Bambah-Mukku et al., 2014). In addition, BDNF signaling
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Significance Statement
Deeper understanding of stimulus-specific regulation of BDNF gene expression is essential to precisely adjust BDNF levels that are
dysregulated in various neurological disorders. Here, we have elucidated the molecular mechanisms behind TrkB signaling-
dependent BDNF mRNA induction and show that CREB family transcription factors are the main regulators of BDNF gene
expression after TrkB signaling. Our results suggest that BDNF-TrkB signaling may induce BDNF gene expression in a distinct
manner compared with neuronal activity. Moreover, our data suggest the existence of a stimulus-specific distal enhancer modu-
lating BDNF gene expression.
The Journal of Neuroscience, February 12, 2020 • 40(7):1405–1426 • 1405
in adult brain is involved in neurogenesis and dendrite formation
of hippocampal granule neurons (Wang et al., 2015; Vilar and
Mira, 2016).
BDNF gene expression is regulated in a sophisticated manner,
with the transcription of every 5 exon being controlled by a
separate promoter (Timmusk et al., 1993; Aid et al., 2007; Pruun-
sild et al., 2007) and by numerous transcription factors (e.g.,
NPAS4, USF family, MeCP2, NFAT family, and CREB) in re-
sponse to various stimuli (for review, see West et al., 2014). In-
terestingly, disruption of specific BDNF transcripts has proven
important roles for different BDNF promoters in the formation
of neural circuits underlying social behavior (Maynard et al.,
2016, 2018).
The cAMP-response element-binding (CREB) family of tran-
scription factors consists of three functionally redundant basic-
leucine zipper transcription factors, namely, CREB protein,
activating transcription factor 1 (ATF1), and cAMP-response el-
ement modulator (CREM) (Mayr and Montminy, 2001). The
role of CREB family in the CNS has been investigated thoroughly
(for review, see Barco and Marie, 2011), and CREB family has
been shown to support neuronal survival (Mantamadiotis et al.,
2002), regulate neuronal migration (Díaz-Ruiz et al., 2008),
modulate synaptogenesis (Aguado et al., 2009), and contribute to
the formation of LTP and long-term memory (Bourtchuladze et
al., 1994). The CREB family has two types of coactivators. First,
CREB binding protein (CBP) and its paralogue p300 (Lundblad
et al., 1995), which interact with Ser-133-phosphorylated CREB
and function via histone acetyl transferase activity (Bannister and
Kouzarides, 1996) or interaction with basal transcriptional ma-
chinery (Kwok et al., 1994; Kee et al., 1996). Second, the CREB-
regulated transcription coactivators (CRTC-s) that are localized
in the cytoplasm, but in response to increase in cytoplasmic
cAMP and Ca 2 levels can be dephosphorylated and transported
to the nucleus (Bittinger et al., 2004) where they bind to the CREB
leucine zipper domain to stabilize the CREB dimer (Luo et al.,
2012; Song et al., 2018) and interact with general transcription
factors (Conkright et al., 2003). The use of different coactivators
allows for a differential activation of cAMP-responsive element
(CRE)-containing promoters in response to diverse stimuli in
different cell types.
BDNF can modulate its own mRNA expression via activation
of the TrkB receptor and downstream MAPK signaling (Yasuda
et al., 2007; Nakajima et al., 2015; Tuvikene et al., 2016). Further-
more, BDNF-TrkB signaling has been shown to induce the ex-
pression of all the BDNF transcripts in cultured rat cortical
neurons (Tuvikene et al., 2016) and BDNF exon IV-containing
transcripts in the rat hippocampus in vivo (Wibrand et al., 2006;
Bambah-Mukku et al., 2014). The induction of BDNF exon
I-containing transcripts is directly, while BDNF exon III- and
VI-containing transcripts are indirectly, regulated by AP-1 tran-
scription factors after BDNF-TrkB signaling (Tuvikene et al.,
2016). The induction of BDNF exon IV-containing transcripts is
mediated by C/EBP after inhibitory avoidance training-induced
BDNF-TrkB signaling (Bambah-Mukku et al., 2014). Still, the
complete repertoire of transcription factors and cis-elements in-
volved in BDNF transcriptional autoregulation has not been de-
scribed. Here, we have investigated the molecular mechanism of
BDNF transcriptional autoregulation in rat cortical neurons and
show that CREB family transcription factors together with
coactivator CBP are the main regulators of TrkB signaling-
dependent induction of all the major BDNF transcripts.
Materials and Methods
Primary cultures of rat cortical neurons. All animal procedures were per-
formed in compliance with the local ethics committee. Primary cultures
of cortical neurons were generated from Sprague Dawley rat male and
female pups at embryonic day 20 –21. Cerebral cortices together with
hippocampi were dissected and preserved in Leibovitz L15 media (PAA
Laboratories) until further processing. Cortices and hippocampi were
cut into small pieces and incubated in 1 ml 0.25% Trypsin-EDTA 1
solution (Invitrogen) at 37°C for 10 min. Next, final concentrations of
0.5 mg/ml DNase I (Roche Diagnostics) and 12 mM MgSO4 were added,
and the mixture was again incubated at 37°C for 10 min. Then, 275 l of
1% trypsin inhibitor (Invitrogen), 110 l of 10% BSA (Pan-Biotech), and
50 l DNase I (stock solution 5 mg/ml, Roche Diagnostics) were added
and tissue was triturated 5 times using 1 ml pipette tip. After trituration,
tissue suspension was diluted in 1 Hank’s buffered salt solution and
centrifuged at 200  g for 30 s. Supernatant was transferred to a new tube
and centrifuged again at 200  g for 6 min. Finally, the supernatant was
removed, and precipitated cells were resuspended in growth medium
containing prewarmed Neurobasal A (PAA Laboratories or Invitrogen),
1 B27 Supplement (Invitrogen), 100 U/ml penicillin and 0.1 mg/ml
streptomycin (Invitrogen), or 100 g/ml Primocin (InvivoGen), 1 mM
L-glutamine (Invitrogen). Cell suspension was distributed to plates pre-
viously coated with 0.2 mg/ml poly-L-lysine (Sigma Millipore) in 0.1 M
borate buffer overnight at 4°C or at least 1 h at room temperature. Cells
were grown at 37°C in 5% CO2 atmosphere. At 2 DIV, half of the growth
medium, or the whole media when the neurons were transduced with
lentiviral particles, was changed and a final concentration of 10 M mi-
totic inhibitor 5-fluoro-2-deoxyuridine (Sigma Millipore) was added.
Neurons were transduced with lentiviral particles at 0 DIV, or with
adeno-associated viral (AAV) vectors at 2 DIV after medium change at
3 multiplicity of infection. The cells were treated at 7– 8 DIV with 50
ng/ml BDNF (Peprotech), 20 g/ml cycloheximide (CHX, Tocris Biosci-
ence), or 5 M CBP-CREB interaction inhibitor (CCII, catalog #217505,
lot 2758191, Merck Millipore). Control cells were treated with respective
volume of vehicle (DMSO or water). For the lentivirus-mediated over-
expression of E1A, neurons were transduced at 5 DIV, 72 h before lysing
the cells after BDNF treatment, as prolonged overexpression of E1A led
to neuronal death.
Viral vectors. The plasmids containing dominant-negative inhibitory
protein coding sequences were obtained from Addgene: CMV500 A-CREB
(plasmid #33371), CMV500 A-C/EBP (plasmid #33352), CMV500 A-C/
EBP (plasmid #33363), CMV500 A-ATF2 (plasmid #33362), CMV566
A-USF (plasmid #33360), and GFP-VIVIT (plasmid #11106). The re-
spective coding sequences were cloned to pAAV vector (AAV Helper-
Free System, Agilent Technologies) under the control of human
Synapsin I promoter. For A-USF, HA-tag was replaced with FLAG-tag.
The coding sequences used for overexpression are listed in Tuvikene,
2018. Production of AAV particles and estimation of viral titer were
performed as described previously (Koppel et al., 2015).
Lentivirus transfer plasmid pLV-hU6-sgRNA-hUbC-dCas9-KRAB-
T2A-GFP coding for repressive dCas9-KRAB was obtained from Add-
gene (plasmid #71237), from which the gRNA expression cassette was
removed using PacI restriction enzyme (Thermo Fisher Scientific). Spe-
cific guide RNA (gRNA) targeting sequences (Tuvikene, 2018) were de-
signed using the Benchling Platform and cloned into pRRL-U6-gRNA-
hPGK-EGFP lentiviral plasmid, where the expression of gRNA is under
the control of U6 promoter and EGFP is under the control of human
PGK promoter. Cloned plasmids were transformed into STBL3 compe-
tent cells (Invitrogen) and purified from bacteria using PureLink HiPure
Plasmid Midiprep Kit (Invitrogen). Finally, all gRNA plasmids were ver-
ified by sequencing. For overexpressing EGFP, A-CREB, E1A, and
dominant-negative CRTC, the respective coding regions (Tuvikene,
2018) were cloned into pRRL vector under the control of human PGK
promoter, with A-CREB, E1A, and dominant-negative CRTC having an
N-terminal FLAG-tag. Production of lentiviral particles was performed
as described by Koppel et al. (2018). Relative titers of lentiviral particles
were estimated by measuring provirus incorporation using qPCR. For
further experiments, equal amounts of functional viral particles were
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used to transduce neurons, and 95% transduction efficiency was veri-
fied by EGFP expression.
RNA extraction and qRT-PCR. For RNA extraction, the neurons were
lysed at 7– 8 DIV in RLT lysis buffer and RNA was purified using
RNeasy Mini Kit (QIAGEN) with on-column digestion of genomic
DNA using RNase-Free DNase Set (QIAGEN). Concentrations of the
purified RNAs were determined with BioSpec-nano spectrophotometer
(Shimadzu). An equal amount of RNA within an experiment was taken for
complementary DNA (cDNA) synthesis using SuperScript III Reverse
Transcriptase (Thermo Fisher Scientific) or SuperScript IV Reverse
Transcriptase (Thermo Fisher Scientific). qPCR was performed using
LightCycler 480 SYBR Green I Master kit (Roche Diagnostics) or HOT
FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne) and LightCycler 480
Instrument II (Roche Diagnostics). Primers and annealing temperatures
are listed in Tuvikene, 2018. All mRNA expression levels were normal-
ized to HPRT1 expression levels. Data were log-transformed, mean-
centered and autoscaled as suggested by Willems et al. (2008) before
statistical analysis.
Luciferase reporter assay. Plasmids containing different rat BDNF
(rBDNF ) and human BDNF (hBDNF ) promoters (p) have been de-
scribed previously as follows: pGL4.15 rBDNF pI (Pruunsild et al., 2011),
pGL4.15 rBDNF pIV and pGL4.15 rBDNF pIV CRE site mutant (Koppel
and Timmusk, 2013), pGL4.15 rBDNF pIII and pGL4.15 rBDNF pVI
(Tuvikene et al., 2016); pGL4.15 hBDNF pI 5, pGL4.15 hBDNF pIV,
pGL4.15 hBDNF pIXa, and respective CRE site mutants (Pruunsild et al.,
2011). pGL4.29 CRE reporter construct (Promega, #9PIE847) was used
as a positive control. rBDNF pI 5 region was generated from pGL4.15
rBDNF pI plasmid. rBDNF pII and pIXa sequences were generated
from rat genomic DNA using Phusion Hot Start II DNA Polymerase
(Thermo Fisher Scientific), and respective regions were cloned into
pGL4.15 vector (Promega) in front of Firefly luciferase coding se-
quence and verified by sequencing. CRE site mutagenesis in rBDNF pI
and pI 5 was performed as published by Pruunsild et al. (2011). The
genomic coordinates of BDNF proximal promoter regions and re-
spective CRE site mutations used in the reporter constructs are shown
in Tuvikene, 2018.
Cultured neurons were transfected at 6 DIV on 48-well plate in dupli-
cate wells using ratio of 1:2 of total DNA and Lipofectamine 2000 Reagent
(Invitrogen). Per well, 250 ng of effector plasmid (pAAV-hSynI-EGFP or
pAAV-hSynI-A-CREB), 250 ng (or 500 ng if no effector was used) of
Firefly luciferase reporter plasmid, and 20 ng of mouse PGK/pGL4.83
plasmid expressing Renilla luciferase for normalization were transfected.
At 7 or 8 DIV, as indicated in the figure legend, neurons were lysed in 1
Passive lysis buffer (Promega). Luciferase signal was measured with
Dual-Glo Luciferase Assay System (Promega) using Genios Pro Multi-
function Microplate Reader (Tecan Group).
For data analysis, Firefly luciferase signal was background-corrected
and normalized to background-corrected Renilla luciferase signal. The
averages of duplicate wells were calculated, data were log-transformed,
and statistical analysis was performed. For CRE reporter experiments
using CRTC1 knockdown and overexpression of dominant-negative
CRTC, log-transformed data were also mean-centered and autoscaled
before statistical analysis.
Western blot. Cultured neurons were lysed in 1 Laemmli buffer in-
cluding 5% -mercaptoethanol. Proteins were separated using 10%
SDS-PAGE and transferred to PVDF membrane (Merck Millipore) in
Towbin buffer at 100 V for 100 min using Mini Trans-blot Cell system
(Bio-Rad). The membrane was blocked in 5% skimmed milk in TBST
buffer (1 Tris-buffered saline, pH 7.4, and 0.1% Tween 20; Amresco),
and then incubated with primary antibody -CREB (1:1000, catalog #06-
863, lot 2446851, Merck Millipore) and with secondary antibody goat
anti-rabbit IgG conjugated with HRP (1:5000, Thermo Fisher Scientific)
in 2% skimmed milk (AppliChem) in TBST at 4°C overnight and at room
temperature for 1 h, respectively. After both incubations, the membrane
was washed 3 times with TBST for 5 min at room temperature. Chemi-
luminescence signal was produced with SuperSignal West Femto Maxi-
mum Sensitivity Substrate (Thermo Fisher Scientific), and the
membrane was exposed to imaging system ImageQuant Las 4000 (GE
Healthcare Life Sciences).
For reprobing, the membrane was stripped with warm 0.1 M glycine
solution, pH 2.0, blocked again as described previously, and incubated
with primary antibody -P-CREB (1:5000, catalog #9198, lot 0010, Cell
Signaling Technology) in 5% BSA (Naxo) in TBST at 4°C overnight.
Further procedure was performed as described previously. For loading
control, the membrane was stained with Coomassie solution (0.1% Coo-
massie Brilliant Blue R-250 Dye, 25% ethanol, 7% acetic acid) for 15 min,
followed by 2 washes with destaining solution (30% ethanol, 10% acetic
acid) for 5 min and rinsing with tap water. The membrane was imaged
using ImageQuant Las 4000 (GE Healthcare Life Sciences).
CREB and P-CREB signals and total protein staining were quantified
using densitometric analysis on ImageQuant TL software (GE Health-
care Life Sciences). CREB protein levels were normalized to total protein
levels, and P-CREB protein levels were normalized to CREB protein
levels. Data were log-transformed, mean-centered, and autoscaled; and
statistical analysis was performed.
Immunocytochemistry. Immunocytochemistry was performed as de-
scribed by Koppel et al. (2018) using CRTC1 antibody (1:1500, catalog
#2587, lot 3, Cell Signaling Technology) and goat anti-rabbit IgG conju-
gated with Alexa-488 (1:2000, Invitrogen) secondary antibody. Hoechst
33324 was used to visualize nuclei. Analysis was performed with LSM 510
META (Carl Zeiss). The specificity of the CRTC1 antibody in immuno-
cytochemistry was verified using CRTC1 knockdown with CRISPR in-
terference in neurons (data not shown).
Chromatin immunoprecipitation (ChIP). Cultured neurons were
grown on 100 mm dishes; and at 7 DIV, the cell growth media was
reduced to 5 ml during BDNF treatment and proteins were crosslinked to
DNA by adding 500 l crosslinking buffer (11% formaldehyde, 100 mM
NaCl, 0.5 mM EGTA, 50 mM HEPES, pH 8.0) and incubating at room
temperature for 10 min for CREB and P-CREB ChIP. Crosslinking was
stopped by adding final concentration of 0.12 M glycine and incubating at
room temperature for 10 min. Subsequently, the cells were washed twice
with 10 ml ice-cold 1 PBS and lysed in 500 l lysis solution (1% SDS, 10
mM EDTA, pH 8.0, 50 mM Tris-HCl, pH 8.0, 1 cOmplete protease
inhibitor cocktail, Roche Diagnostics; 1 PhosSTOP phosphatase inhib-
itor cocktail, Roche Diagnostics) for 5 min on ice. Cells were collected
with cell scraper and transferred to an Eppendorf tube where lysates were
sonicated on ice using VCX-130 sonicator (Sonics) until an approximate
average fragment size of 250 –500 bp was obtained. Following sonication,
the lysates were centrifuged at 16 000  g for 5 min at 4°C, and superna-
tant was transferred to a new tube.
Protein concentration was determined using Pierce BCA Protein As-
say Kit (Thermo Fisher Scientific); and where necessary, the concentra-
tions were equalized using lysis buffer. Equal amounts of protein were
diluted 9 times in dilution buffer (1% Triton X-100, 150 mM NaCl, 2 mM
EDTA, pH 8.0, 20 mM Tris-HCl, pH 8.0, 1 cOmplete protease inhibitor
cocktail, Roche Diagnostics; 1 PhosSTOP phosphatase inhibitor cock-
tail, Roche Diagnostics). A total of 5 g of -CREB (catalog #06-863, lot
2446851, Merck Millipore) or -P-CREB (catalog #9198, lot 0010, Cell
Signaling Technology) was added to the diluted lysate and incubated
overnight at 4°C. In parallel, 50 l Dynabeads Protein G (Invitrogen) per
immunoprecipitation reaction were washed twice with 1 ml dilution
buffer for 10 min at 4°C and blocked overnight at 4°C in 1 ml dilution and
lysis buffer solution (ratio of 9:1, respectively), containing 200 g/ml
BSA and 10 g/ml salmon sperm DNA. The next day, the beads were
washed twice with dilution buffer for 10 min at 4°C and finally diluted in
dilution and lysis buffer solution (ratio of 9:1, respectively), distributed
to samples, and incubated for 5 h with rotation at 4°C. Then, the
beads-antibody complexes were washed 4 times in 1 ml wash buffer (1%
Triton X-100, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, pH 8.0, 20 mM
Tris-HCl, pH 8.0, 1 cOmplete protease inhibitor cocktail, Roche Diag-
nostics; 1 PhosSTOP phosphatase inhibitor cocktail, Roche Diagnos-
tics) and once with final wash buffer (1% Triton X-100, 0.1% SDS, 500
mM NaCl, 2 mM EDTA, pH 8.0, 20 mM Tris-HCl, pH 8.0, 1 cOmplete
protease inhibitor cocktail, Roche Diagnostics; 1 PhosSTOP phospha-
tase inhibitor cocktail, Roche Diagnostics) for 10 min per wash while
rotating at 4°C. DNA-protein complexes were eluted from the beads 3
times with 50 l elution buffer (1% SDS, 100 mM NaHCO3, 1 mM EDTA)
at 37°C for 10 min. The third elution was performed with an additional
Esvald, Tuvikene et al. • CREB Family in BDNF Transcriptional Autoregulation J. Neurosci., February 12, 2020 • 40(7):1405–1426 • 1407
incubation at 65°C for 5 min before combining with other eluates. Input
samples were diluted with elution buffer to a final volume of 150 l.
Crosslinking was reversed by adding final concentration of 250 mM NaCl
and incubating at 65°C overnight.
The next day, 125 g/ml RNase A was added to the samples and
incubated at 37°C for at least 30 min. After that, final concentrations
of 6 mM EDTA and 240 g/ml proteinase K were added and incubated
at 45°C for at least 30 min. Finally, genomic DNA was purified using
QIAquick PCR Purification Kit (QIAGEN), and DNA enrichment
was analyzed using qPCR. Primers and annealing temperatures are
listed in Tuvikene, 2018. The efficiencies of primer pairs were deter-
mined using serial dilutions of input DNA. DNA enrichment was
calculated relative to the respective DNA levels in input sample con-
sidering primer pair efficiency. For statistical analysis, data were
log-transformed.
CBP ChIP followed the described protocol, except for the following
modifications: crosslinking with formaldehyde was performed for 20
min; sonication was performed with BioRuptor Pico (Diagenode);
7.5–10 g of -CBP (catalog #7389, lot 5, Cell Signaling Technology)
antibody was used; phosphatase inhibitors were not used; washes with
ice-cold solutions were performed quickly without rotation. For CBP
ChIP, data were log-transformed and also mean-centered to account for
variations in enrichment between different experiments.
Electrophysiology and intrahippocampal infusion of BDNF. Intrahip-
pocampal BDNF infusion was performed as described previously (Ying
et al., 2002; Messaoudi et al., 2007; Kuipers et al., 2016). All experiments
were performed according to the ethical standards approved by the Nor-
wegian Committee for Experiments on Animals. The experiments were
performed on adult male rats of the Sprague Dawley strain (Taconic),
weighing 250 –350 g. Rats were anesthetized with urethane (1.5 g/kg,
i.p.), and positioned in a stereotaxic frame, while the body temperature
was maintained at 37°C using thermostatically controlled electric heating
pad. A concentric bipolar stimulating electrode (Tip separation 500 m;
SNEX 100; Rhodes Medical Instruments) was lowered into the angular
bundle for stimulation of the medial perforant path. Stereotaxic coordi-
nates for stimulation were as follows (in mm): 7.9 posterior to bregma,
4.2 lateral to the midline, and 2.5 below the dura.
A Teflon-coated tungsten wire recording electrode (outer diameter of
0.075 mm; A-M Systems #7960) was glued to the infusion cannula (30
gauge). The electrode was then cut so that it extended 800 m from the
end of the cannula. Stereotaxic coordinates for recording in the dentate
hilus were as follows (in mm): 3.9 posterior to bregma, 2.3 lateral, and
2.8 –3.1 below the dura. The recording electrode was slowly lowered into
the dorsal hippocampus until a positive-going fEPSP of maximum slope
was obtained in the dentate hilus. The tip of the infusion cannula was
located in the deep striatum lacunosum-moleculare of field CA1, 800 m
above the hilar recording site and 300 – 400 m above the medial per-
forant synapses. The infusion cannula was connected via a polyethylene
(PE50) tube to a 10 l Hamilton syringe and infusion pump. After base-
line recording for 20 min, the infusion of 2 l of 1 g/l BDNF (Alo-
mone Labs) over 25 min at a rate of 0.08 l/min followed. cytochrome C
(CytC; Sigma Millipore) was used as a control for BDNF infusion.
Evoked responses were recorded for 120 min after infusion.
Biphasic rectangular test pulses of 150 s duration were applied every
30 s throughout the experiment (0.033 Hz). Responses were allowed to
stabilize for 1 h at a stimulation intensity that produced a population
spike 30% of maximum. A stable 20 min baseline of evoked potentials
was recorded (pulse-width 0.15 ms, at 0.033 Hz) before intrahippocam-
pal drug infusion. Evoked responses were recorded for 120 min after
infusion. Signals from the dentate hilus were amplified, filtered (0.1 Hz to
10 kHz), and digitized (25 kHz). Acquisition and analysis of field poten-
tials were accomplished using DataWave Technologies. The maximum
slope of the fEPSP and the averages of four consecutive responses were
obtained. Changes in the fEPSP slope were expressed in percentage of
baseline (20 min preceding infusion). After recordings were completed,
the electrodes were removed, rats were decapitated, and dentate gyri
from both ipsilateral and contralateral hemisphere were dissected, im-
mediately frozen on dry ice, and stored at 80°C. RNA was purified
using RNeasy Lipid Tissue Mini Kit (QIAGEN), and qRT-PCR was per-
formed as stated previously.
Statistical analysis and graphical representation of the data. Statistical
analysis was performed on log-transformed, and where applicable,
mean-centered and autoscaled data from independent experiments:
neuron cultures obtained from different litters and prepared separately;
or independent animals for the in vivo experiments. Two-tailed paired or
unpaired t tests, as indicated at each figure, were performed using Mi-
crosoft Excel 365. All tested hypotheses were specified before conducting
the experiments. p values were adjusted for multiple comparisons with
Holm–Sidak family-wise error rate correction method using Prism 7.03
(GraphPad Software). For graphical representation, means and means 
SEM of transformed data were calculated and data were back-
transformed to linear scale with error bars indicating upper and lower
limits of back-transformed mean  SEM.
Results
BDNF transcriptional autoregulation requires
protein synthesis
Currently, only AP-1 and C/EBP transcription factors have
been shown to be involved in BDNF transcriptional autoregula-
tion in neurons. To extend the understanding of BDNF tran-
scriptional autoregulation, we decided to perform a thorough
analysis of additional transcription factors involved. We first
asked whether the transcription factors that regulate BDNF ex-
pression in primary cultures of cortical neurons are synthesized
in response to BDNF-TrkB signaling (like the AP-1 proteins) or
are present in the cell before activation of TrkB signaling. There-
fore, we treated cultured rat cortical neurons with the protein
synthesis inhibitor CHX before BDNF treatment and measured
the expression levels of different BDNF transcripts using qRT-
PCR (Fig. 1).
First, as a positive control of CHX treatment, we determined
the expression levels of c-Fos, as it is known that the induction of
c-Fos mRNA is largely independent of protein synthesis (Green-
berg et al., 1986; Hughes et al., 1993). In cells pretreated with
CHX, 1 h of BDNF treatment induced c-Fos expression level
24-fold (p 	 0.0006), and the expression levels remained high
for 3 h (31-fold, p 	 0.0056) and 6 h (14-fold, p 	 0.0116) of
BDNF treatment (Fig. 1). Next, we measured the induction of
BDNF mRNA levels after BDNF-TrkB signaling. Without dis-
rupting protein synthesis, the induction of total BDNF mRNA
was 3.6-fold (p 	 0.0737) after 1 h, 13-fold (p 	 0.0034) after
3 h and 6.7-fold (p 	 0.0152) after 6 h of BDNF-TrkB signal-
ing. Blocking protein synthesis reduced the induction of total
BDNF mRNA to 1.8-fold (p 	 0.0325) after 1 h, to 1.6-fold
(p 	 0.2899) after 3 h of BDNF treatment, and after 6 h of BDNF
treatment the expression levels were approximately similar to the
expression levels in cells not treated with BDNF. At different
transcript level, blocking protein synthesis completely abolished
the TrkB signaling-dependent induction of BDNF exon I-, III-,
and IXa-containing transcripts. In contrast, the early induction
of BDNF exon IV-containing transcripts remained after CHX
treatment, in which case after 1 h of BDNF treatment a 2.8-fold
(p 	 0.0035) induction was still observed, while the induction in
cells not treated with CHX at the respective time point was 6.3-
fold (p 	 0.0618). In CHX-treated cells, we also observed a minor
1.4-fold (p 	 0.0379) and 1.3-fold (p 	 0.0417) induction of
BDNF exon IIc- and VI-containing transcripts, respectively, after
1 h of BDNF treatment, while the induction of these transcripts in
cells not treated with CHX at the same time point was 1.6-fold
(p 	 0.2181) and 1.8-fold (p 	 0.0845), respectively. Together,
our results indicate that at least some transcription factors neces-
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sary for the early induction of BDNF exon IIc-, IV-, and VI-
containing transcripts after BDNF-TrkB signaling are already
present in the cell, while the transcription factors that participate
in later induction after BDNF-TrkB signaling or regulate other
BDNF transcripts are mostly synthesized in response to BDNF-
TrkB signaling.
CREB family of transcription factors is the main mediator of
the early phase of BDNF transcriptional autoregulation
To investigate which transcription factors, in addition to AP-1,
are involved in BDNF transcriptional autoregulation in cultured
rat cortical neurons, we used dominant-negative forms of several
transcription factor families to impair their potential regulatory
role. We focused on transcription factors that have been shown to
be involved in BDNF transcriptional regulation in other signaling
pathways, particularly on those that are present in the neurons
before TrkB signaling and are activated independent of transla-
tion. We created AAV vectors encoding the dominant-negative
forms of CREB, C/EBP and , ATF2, USF, and NFAT families.
The dominant-negative proteins A-CREB, A-C/EBP, A-C/
EBP, A-ATF2, and A-USF mediate their dominant-negative ef-
fect through dimerization with the respective endogenous
transcription factors, thus preventing the transcription factor
from binding to DNA and mediating transcriptional regulation
(Krylov et al., 1995; Ahn et al., 1998; Qyang et al., 1999). To
interfere with NFAT-regulated gene expression, we used overex-
pression of the VIVIT protein sequence (MAGPHPVIVITG-
PHEE) that blocks NFAT dephosphorylation by calcineurin and
thus prevents NFAT translocation to the nucleus (Aramburu et
al., 1999). We verified the expression of the dominant-negative
proteins using immunocytochemistry and Western blot analysis
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Figure 1. BDNF transcriptional autoregulation requires protein synthesis. At 7 DIV, rat primary cortical neurons were treated with 20 g/ml CHX for 30 min where indicated and subsequently
with 50 ng/ml BDNF for the indicated time periods. qRT-PCR was used to measure the levels of c-Fos, total BDNF (BDNF coding), and BDNF transcripts. The mRNA fold induction was calculated relative
to the respective mRNA level in cells not treated with BDNF and either not treated or treated with CHX, respectively. Average of three independent experiments (n 	 3) is shown. Error bars indicate
SEM. Statistical significance relative to the respective transcript levels in cells not treated with BDNF: ***p 
 0.001; **p 
 0.01; *p 
 0.05 (paired two-tailed t test, corrected for multiple
comparisons using Holm–Sidak method).
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AAV vectors at 2 DIV, treated the cells with BDNF at 8 DIV, and
measured the expression levels of BDNF using qRT-PCR (Fig. 2).
The strongest effect on BDNF transcriptional autoregulation
was seen in cells overexpressing A-CREB, where the basal expres-
sion level of total BDNF mRNA was reduced to 0.69-fold (p 	
0.0266) compared with BDNF expression levels in neurons over-
expressing EGFP. In BDNF-treated cells, the overexpression of
A-CREB decreased the induced levels of total BDNF mRNA from
5.2-fold to 0.56-fold (p 	 0.0252) after 1 h of BDNF treatment
and from 16.8-fold to 6.0-fold (p 	 0.0054) after 3 h of BDNF
treatment. No significant difference between the induced levels of
BDNF in EGFP and A-CREB-overexpressing cells was seen at 6 h
of BDNF treatment.
Notably, we did not observe a noteworthy effect of overexpressing
A-ATF2, A-USF, A-C/EBP, A-C/EBP, or EGFP-VIVIT on the basal
levels of BDNF mRNA or on TrkB signaling-induced BDNF lev-
els, indicating that ATF2, USF, C/EBP, and NFAT family tran-
scription factors do not significantly contribute to the BDNF
autoregulatory loop in cortical neurons.
As A-CREB had the most prominent effect on BDNF autoreg-
ulation, we next investigated the effect of overexpressing A-CREB
on the levels of different BDNF transcripts (Fig. 3). The induced
levels of exon I-containing BDNF transcripts showed a remark-
able decrease from 159-fold to 52-fold (p 	 0.1082, uncorrected
p 	 0.0282) at 3 h of BDNF treatment. A similar effect was seen






























































































































Figure 2. CREB family transcription factors are the main regulators of BDNF transcriptional autoregulation. Primary neurons were transduced at 2 DIV with AAV particles coding for indicated
dominant-negative transcription factors or EGFP. At 8 DIV, neurons were treated with 50 ng/ml BDNF for the indicated time periods, and the expression levels of total BDNF mRNA (BDNF coding) were
measured using qRT-PCR. The expression level of respective transcripts in cells transduced with EGFP-encoding AAV particles and not treated with BDNF was set as 1. Average of three independent
experiments (n 	 3) is shown. Error bars indicate SEM. Statistical significance between the respective transcript levels in EGFP and respective dominant-negative-overexpressing cells at respective
time points: **p 
 0.01; *p 
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Figure 3. CREB family transcription factors are required for the early induction of all BDNF transcripts in response to BDNF-TrkB signaling. Primary neurons were transduced at 2 DIV with AAV
particles coding for EGFP or A-CREB, a dominant-negative form of CREB family transcription factors. At 8 DIV, neurons were treated with 50 ng/ml BDNF for the indicated time periods; and the
expression levels of different BDNF transcripts, as indicated above each graph, were measured using qRT-PCR. The expression level of respective transcripts in cells transduced with EGFP-encoding
AAV particles and not treated with BDNF was set as 1. Average of three independent experiments (n 	 3) is shown. Error bars indicate SEM. Statistical significance between the respective transcript
levels in EGFP and A-CREB-overexpressing cells at respective time points: *p 
 0.05 (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak method).
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treatment, when the induced levels of these transcripts decreased
from 8.8-fold to 3.7-fold (p 	 0.2775, uncorrected p 	 0.15002)
and from 7.0-fold to 1.6-fold (p 	 0.0776, uncorrected p 	
0.0200), respectively.
Overexpression of A-CREB decreased the basal levels of only
BDNF exon IV-containing transcripts to 0.4-fold (p 	 0.0575,
uncorrected p 	 0.0292) compared with the respective levels in
neurons expressing EGFP. Remarkably, A-CREB also completely
abolished the induction of exon IV-containing transcripts at 1 h
(p 	 0.0119) of BDNF-TrkB signaling and lowered the induced
levels at 3 h from 20-fold to 4.7-fold (p 	 0.0119). A similar
tendency was observed for BDNF exon VI- and IXa-containing
transcripts, where A-CREB abolished the induction completely at
1 h time point (p 	 0.1078, uncorrected p 	 0.0281, and p 	
0.0343, respectively). However, at 6 h of BDNF treatment, the
induced levels of all BDNF transcripts were mostly the same in
A-CREB and EGFP-overexpressing cells, indicating that other
transcription factors outside the CREB family mediate the late
induction of BDNF expression in response to TrkB signaling.
As the human Synapsin I promoter used in our AAV vectors is
slightly (2-fold) upregulated in response to BDNF-TrkB signal-
ing (data not shown), we verified the results of A-CREB overex-
pression using lentiviral vectors expressing EGFP or A-CREB
under the control of human PGK promoter, which provides very
stable expression in response to BDNF treatment (data not
shown). The results obtained using lentivirus-mediated overex-
pression (n 	 3, data not shown) were remarkably similar to
those obtained with AAV vectors, further strengthening the no-
tion that CREB family transcription factors are the main media-
tors of the early, but not late, induction of all BDNF transcripts
upon TrkB signaling.
CREB is rapidly phosphorylated in
response to BDNF-TrkB signaling
To confirm BDNF signaling-dependent
activation of CREB, as it has been de-
scribed previously (Finkbeiner et al.,
1997; Pizzorusso et al., 2000), in our pri-
mary cultures of neurons, we treated neu-
rons with BDNF for different time periods
and measured changes in the expression
levels of CREB1 mRNA using qRT-PCR
and determined CREB and phospho-Ser-
133 CREB protein levels using Western
blot (Fig. 4).
BDNF treatment did not affect CREB1
mRNA expression level (Fig. 4A). Al-
though a small downregulation of CREB1
mRNA level in response to BDNF-TrkB
signaling was consistently observed after 3
h of BDNF treatment, the minor changes
in CREB1 mRNA levels were not reflected
in CREB protein levels, which remained
stable (Fig. 4B,C). In contrast, BDNF-
TrkB signaling induced very rapid CREB
phosphorylation at Ser-133 (Fig. 4B,D),
as expected, considering that post-trans-
lational regulation of CREB is well estab-
lished (for review, see Johannessen et al.,
2004). P-CREB levels were 6.5-fold
(p 	 0.00004) higher after 0.5 h, 5.0-
fold (p 	 0.0105) higher after 1 h, and
stayed 2-fold higher after 3 and 6 h of
BDNF treatment compared with P-CREB
levels in untreated cells. Together, our results indicate that the
activity of CREB after BDNF-TrkB signaling in our neuronal
cultures is largely regulated through post-translational means
and not by overall change in CREB protein levels.
CREB coactivator CBP/p300 is necessary for the BDNF
transcriptional autoregulation
As the overexpression of A-CREB mostly decreased the early in-
duction, largely corresponding to the period where CREB is
phosphorylated, but not the late induction of different BDNF
transcripts in response to BDNF-TrkB signaling, we next inves-
tigated whether CREB coactivator CBP, which interacts with Ser-
133 phosphorylated CREB, is involved in regulating the
expression of BDNF transcripts after BDNF-TrkB signaling. For
that, we used CBP-CREB interaction inhibitor (CCII), which
binds to CBP’s KIX domain (Best et al., 2004; B. X. Li and Xiao,
2009) and therefore prevents CBP interaction with CREB family
members. As p300, a paralogue of CBP, has a highly similar KIX
domain, CCII also inhibits CREB-p300 interaction (Breen and
Mapp, 2018). We treated cultured rat neurons with CCII before
treating the cells with BDNF for different time periods and then
measured the levels of BDNF transcripts using qRT-PCR (Fig. 5).
First, we observed no remarkable effect of CCII on the expres-
sion of c-Fos mRNA in response to BDNF-TrkB signaling (Fig. 5).
On the contrary, disturbing CBP/p300 recruitment decreased
BDNF transcriptional autoregulation and affected the induced
levels of most of the BDNF transcripts, whereas the basal expres-
sion levels of BDNF transcripts did not change. The induced
levels of total BDNF mRNA were reduced from 3.0-fold to
2.0-fold (p 	 0.2236, uncorrected p 	 0.0809) after 1 h, and
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Figure 4. BDNF-TrkB signaling induces CREB phosphorylation but does not influence total CREB protein levels. Primary neurons
were treated at 7 DIV with 50 ng/ml BDNF for the indicated time periods. A, CREB1 mRNA levels, measured using qRT-PCR, are
represented as fold induction relative to CREB1 mRNA levels in untreated cells. B, Western blot analysis determining CREB and
phospho-Ser-133 CREB (P-CREB) protein levels and Coomassie staining for loading control. C, Quantification of total CREB protein
levels. CREB protein levels were normalized using Coomassie staining, and normalized CREB protein level in nontreated cells was
set as 1. D, Quantification of CREB phosphorylation levels. P-CREB protein levels were normalized to total CREB protein levels, and
the relative level of P-CREB protein in nontreated cells was set as 1. A, C, D, Average of three independent experiments (n 	 3) is
shown. Error bars indicate SEM. Statistical significance relative to respective mRNA (A) or protein (C, D) levels in untreated cells:
***p 
 0.001; *p 
 0.05 (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak method).
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treatment in CCII-treated cells. In cells pretreated with CCII, the
induced levels of BDNF transcripts containing exon IV and IXa
were decreased from 5.3-fold to 3.2-fold (p 	 0.2972) and
from 8.4-fold to 3.1-fold (p 	 0.1486), respectively, after 1 h
of BDNF treatment, and from 16-fold to 9.9-fold (p 	
0.0647) and from 14-fold to 8.6-fold (p 	 0.1707), respec-
tively, after 3 h of BDNF treatment. The induced levels of BDNF
transcripts containing exon I, IIc, and VI were decreased by 2-
fold (p 	 0.0072, p 	 0.0402, and p 	 0.0359, respectively) in
cells pretreated with CCII after 3 h of BDNF treatment. The ex-
pression levels of BDNF exon III-containing transcripts did not
depend on CBP/p300 recruitment. Interestingly, after 6 h of
BDNF treatment, there were no differences in the induced levels
of most BDNF transcripts, except for exon IIc-containing tran-
scripts, in cells treated with DMSO or CCII, indicating that
CREB-CBP/p300 interaction is largely dispensable for the later
phases of BDNF transcriptional autoregulation.
To further elucidate the role of CBP/p300 in BDNF gene reg-
ulation, we overexpressed adenoviral E1A gene, which encodes
proteins that are known to function as dominant-negative for
CBP/p300 and impair CBP/p300-regulated transcription (Kalva-
kolanu et al., 1992; Lundblad et al., 1995; Nakajima et al., 1997).
First, we noted a (Fig. 6) statistically insignificant 3.3-fold in-
crease (p 	 0.2957, uncorrected p 	 0.1227) in the basal expres-
sion level of c-Fos, and 2-fold decrease (p 	 0.1963,
uncorrected p 	 0.0532) in the induced levels of c-Fos mRNA
after 1 h of BDNF treatment (Fig. 6). Notably, we also observed
that the basal expression of most BDNF transcripts, except for
transcripts containing BDNF exon VI, was upregulated 1.3-fold
to 1.8-fold, and even 4.7-fold (p 	 0.1603, uncorrected p 	
0.0786) for exon I-containing BDNF transcripts, by E1A overex-
pression (Fig. 6). In contrast, the basal levels of exon VI-
containing BDNF transcripts was decreased 2-fold (p 	
0.1980, uncorrected p 	 0.1494) in E1A-expressing cells. The
TrkB signaling-induced levels of total BDNF mRNA were re-
duced from 4.4-fold to 1.7 fold (p 	 0.0456) after 1 h, from
9-fold to 2.6-fold (p 	 0.0458) after 3 h, and from 4.2-fold
to 2-fold (p 	 0.0458) after 6 h of BDNF treatment. Corre-
spondingly, the induced levels of all BDNF transcripts after
BDNF-TrkB signaling were diminished after E1A overexpres-
sion. Notably, the induced levels of BDNF transcripts containing
exon IV were reduced from 6.9-fold to 2.1-fold (p 	 0.0064)
after 1 h, from 8.0-fold to 1.8-fold (p 	 0.0064) after 3 h, and
from 2.8-fold to 1.2-fold (p 	 0.0843, uncorrected p 	 0.0431)
after 6 h of BDNF treatment by E1A overexpression. Together,
our results show that CBP/p300 is absolutely required for the
regulation of BDNF transcription in response to BDNF-TrkB
signaling.
CREB coactivator CRTC does not participate in BDNF
transcriptional autoregulation
Next, to further elucidate the mechanism of CREB family-
regulated BDNF gene expression, we investigated whether other
CREB coactivators are required for the BDNF transcriptional
autoregulation. Three CRTCs have been described, but CRTC1 is
the most abundantly expressed member of the CRTC family in
the CNS (Watts et al., 2011; Saura and Cardinaux, 2017). It has


















































































































































































Figure 5. Early, but not late, phase of BDNF transcriptional autoregulation requires CREB-CBP/p300 interaction. At 8 DIV, primary neurons were treated with 5 M CBP-CREB interaction inhibitor
(CCII) or with DMSO as a control for 1 h before treating the cells with 50 ng/ml BDNF for the indicated time periods. qRT-PCR was used to measure c-Fos, total BDNF (BDNF coding), and BDNF transcript
levels. The expression level of respective transcripts in vehicle-treated cells not treated with BDNF was set as 1. Average of three independent experiments (n 	 3) is shown. Error bars indicate SEM.
Statistical significance between respective transcript levels in DMSO and CCII-treated cells at respective time points: **p 
 0.01; *p 
 0.05 (paired two-tailed t test, corrected for multiple
comparisons using Holm–Sidak method).
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ent BDNF transcripts both in PFC and in hippocampus (Breuil-
laud et al., 2012), suggesting a possible role for CRTC1 in BDNF
gene regulation. Therefore, we first chose to investigate whether
CRTC1 localizes to the nucleus in response to BDNF-TrkB sig-
naling, as it has been established for various treatments (e.g.,
forskolin, membrane depolarization with KCl and NMDA)
(Bittinger et al., 2004; Zhou et al., 2006; S. Li et al., 2009; Ch’ng
et al., 2012; Fukuchi et al., 2014, 2015; Uchida et al., 2017). We
analyzed CRTC1 localization in untreated neurons and neu-
rons treated with BDNF using immunocytochemistry. We
used KCl treatment as a positive control. Our results show
that, in unstimulated cortical neurons, CRTC1 is mainly lo-
calized in the cytoplasm, whereas after 1 h KCl treatment al-
most all of CRTC1 is localized to the nucleus (Fig. 7). After
BDNF treatment, the nuclear localization of CRTC1 increases
in the majority of the cells; however, a detectable amount of
CRTC1 also remains in the cytoplasm. Similar results were
also observed after 3 and 6 h treatments (data not shown).
Together, our data show that CRTC1 is translocated to the
nucleus after BDNF treatment, although with lower efficiency
than after membrane depolarization, and could possibly be
involved in BDNF autoregulation.
Next, to investigate whether CRTC1 regulates BDNF gene ex-
pression after BDNF-TrkB signaling, we suppressed CRTC1 gene
expression using CRISPR interference with lentivirus-mediated
overexpression of dCas9 protein coupled with KRAB repressor
domain, and two gRNAs targeted to CRTC1 promoter region.
We transduced cultured rat neurons with lentiviral particles at 0
DIV, treated neurons with BDNF at 8 DIV, and used luciferase








































































































































































Figure 6. Activity of CBP/p300 is necessary for both the early and late induction of all BDNF transcripts after BDNF-TrkB signaling. Primary neurons were transduced at 5 DIV with lentiviral particles
encoding EGFP, as control, or E1A, a dominant-negative for CBP/p300. At 8 DIV, neurons were treated with 50 ng/ml BDNF for the time indicated. qRT-PCR was used to measure c-Fos, total BDNF
(BDNF coding), and BDNF transcript levels. The expression level of respective transcripts in cells expressing EGFP not treated with BDNF was set as 1. Average of three independent experiments (n 	
3) is shown. Error bars indicate SEM. Statistical significance between respective transcript levels in EGFP and E1A-expressing cells at respective time points: **p 
 0.01; *p 
 0.05 (paired two-tailed
t test, corrected for multiple comparisons using Holm–Sidak method).














Figure 7. CRTC1 localizes to the nucleus after BDNF treatment. At 8 DIV, neurons were
treated with 25 mM KCl, as a positive control, or 50 ng/ml BDNF. Immunocytochemistry was
performed using anti-CRTC1 antibody (green). Hoechst 33324 was used to visualize nuclei
(blue).
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measure the expression levels of BDNF transcripts (Fig. 8). Using
such CRISPR interference system, we succeeded in repressing
CRTC1 mRNA expression 8-fold (p 	 0.1304, uncorrected p 	
0.0413) (Fig. 8B), which also resulted in 2-fold to 3-fold de-
crease in the activation of CRE-reporter at different time points
after BDNF-TrkB signaling (Fig. 8A). For example, CRTC1
knockdown reduced CRE-reporter activation from 24-fold to
8-fold (p 	 0.0006) at 8 h BDNF treatment. However, the reduc-
tion of CRTC1 had no remarkable effect on the induction of any
BDNF transcript after BDNF-TrkB signaling (Fig. 8B). Of note,
no compensatory increase in the expression of CRTC2 and
CRTC3 mRNA was detected in response to repressing the expres-
sion of CRTC1 (data not shown).
Finally, we decided to take a wider approach in studying the
role of CRTC family of CREB coactivators by overexpressing a
dominant-negative protein for CRTC, which consists of the first
44 amino acids of CRTC1 protein. This dominant-negative
CRTC binds to CREB and impairs the interaction of CREB with
the members of CRTC family (used by Bittinger et al., 2004; Zhou
et al., 2006; Kovács et al., 2007; Uchida et al., 2017). As a positive
control, we first determined that overexpression of dominant-
negative CRTC reduces BDNF-TrkB signaling-induced CRE-
reporter activity 2-fold at every measured time point, albeit
statistically insignificantly (Fig. 9A). Meanwhile, overexpression
of dominant-negative CRTC did not affect the basal expression
nor BDNF-TrkB signaling-induced levels of any BDNF transcript
(Fig. 9B). Together, our results show that CREB coactivators
from the CRTC family do not participate in BDNF transcrip-
tional autoregulation.
CRE element in rat BDNF promoter IV is required for the
activation of the promoter after BDNF-TrkB signaling
Next, to determine the role of CREB family transcription factors
in the activation of BDNF proximal promoter regions after
BDNF-TrkB signaling, we used luciferase reporter assay. We
transfected cultured rat neurons with rat BDNF (rBDNF) pro-
moter I, II, III, IV, VI, and IXa constructs, or CRE reporter as a
positive control, together with either EGFP or A-CREB overex-
pression vectors. In addition, we used a short version of rBDNF
promoter I that contains only the 5 transcription start site of the
promoter I, designated here as rBDNF promoter I 5, as it has
been shown to be more inducible than the full-length promoter I
after membrane depolarization (Pruunsild et al., 2011). Finally,
we treated neurons with BDNF and measured promoter activity
using luciferase assay (Fig. 10A).
First, we observed that overexpression of A-CREB reduced the
basal activity of CRE reporter in unstimulated cells 3.4-fold
(p 	 0.0022), and decreased the BDNF-TrkB signaling-induced
activity of the CRE reporter by 11-fold (p 	 0.0061) and by
15-fold (p 	 0.0114) after 4 and 8 h of BDNF treatment, re-
spectively (Fig. 10A), indicating the functionality of our reporter
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Figure 8. CREB coactivator CRTC1 does not participate in the induction of BDNF gene expression after BDNF-TrkB signaling. Primary neurons were transduced at 0 DIV with lentiviral particles
coding for dCas9-KRAB, and a combination of two CRTC1 gRNAs or negative gRNA (neg gRNA). A, Transduced neurons were transfected with CRE-reporter at 6 DIV, and luciferase reporter activity was
measured at 8 DIV after BDNF treatment (n 	 4). Luciferase activity in cells transduced with dCas9-KRAB and negative gRNA-encoding lentiviral particles and not treated with BDNF was set as 1. B,
At 8 DIV, neurons were treated with 50 ng/ml BDNF for the indicated time periods, and the expression levels of CRTC1, total BDNF (BDNF coding), and different BDNF transcripts were measured using
qRT-PCR. The expression level of respective transcripts in cells transduced with dCas9-KRAB and negative gRNA-encoding lentiviral particles and not treated with BDNF was set as 1. Average of three
independent experiments (n 	 3) is shown. Error bars indicate SEM. Statistical significance between the respective transcript levels in negative gRNA and CRTC1 gRNA-overexpressing cells at
respective time points: ***p 
 0.001; **p 
 0.01; *p 
 0.05 (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak method).
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basal activity of rBDNF promoters I, I 5, VI, and IXa. Notably, we
saw a 1.5-fold decrease (p 	 0.0366) in the basal activity of
rBDNF promoter IV in cells overexpressing A-CREB. Interest-
ingly, A-CREB overexpression slightly increased the basal activity
of rBDNF promoters II and III by 1.3-fold (p 	 0.0304) and
1.1-fold (p 	 0.0348), respectively.
Next, we determined that overexpression of A-CREB reduced
the TrkB signaling-dependent activation of rBDNF promoters I, I
5, and IV after 4 h of BDNF treatment from 5.2-fold to 4.0-
fold (p 	 0.1937), from 7.4-fold to 4.9-fold (p 	 0.0012),
and from 2.4-fold to 1.4-fold (p 	 0.0829), respectively. Sim-
ilar tendencies were observed after 8 h of BDNF treatment when
overexpression of A-CREB reduced the BDNF-TrkB signaling-
induced activity of rBDNF promoter I from 6.6-fold to 5.1-
fold (p 	 0.2022, uncorrected p 	 0.1068), promoter I 5 from
12-fold to 8.6-fold (p 	 0.0174), and promoter IV from
3.0-fold to 1.7-fold (p 	 0.0303). Overexpression of A-CREB
enhanced the BDNF-induced activity of rBDNF promoter II and
VI from 2.6-fold to 3.6-fold (p 	 0.0033) and from 1.4-
fold to 1.7-fold (p 	 0.0981, uncorrected p 	 0.0473), respec-
tively, after 4 h, and from 3.0-fold to 4.3-fold (p 	 0.0030)
and from 1.6-fold to 2.0-fold (p 	 0.0981, uncorrected p 	
0.0338), respectively, after 8 h of BDNF-TrkB signaling. The TrkB
signaling-induced activity of rBDNF promoter III was not
changed in response to overexpressing A-CREB. Notably, the
activity of rBDNF promoter IXa was not inducible in response to
BDNF-TrkB signaling, and we could not detect any effect of
A-CREB overexpression on the activity of this promoter region.
As it has been described that rat BDNF promoters I and IV
have a functional CRE element (Shieh et al., 1998; Tao et al., 1998;
Tabuchi et al., 2002), we next investigated the importance of
these CRE elements by overexpressing rBDNF promoter con-
structs where the respective CRE element was mutated (Fig. 10B).
Our results showed that mutating the CRE element slightly de-
creased the induction of rBDNF promoter I from 7.4-fold to
6.1-fold (p 	 0.1845, uncorrected p 	 0.0657) after 4 h, and
from 8.5-fold to 7.1-fold (p 	 0.1331, uncorrected p 	
0.0351) after 8 h of BDNF treatment in cells expressing EGFP
(Fig. 10B). In cells overexpressing A-CREB, the mutation in CRE
element reduced the induction of rBDNF promoter I from 5.5-
fold to 4.9-fold (p 	 0.3463, uncorrected p 	 0.2550) after 4 h,
and from 6.7-fold to 5.4-fold (p 	 0.3463, uncorrected p 	
0.1915) after 8 h of BDNF treatment. A similar effect was ob-
served for rBDNF promoter I 5, in which case the mutation in
CRE element slightly reduced the induction of the promoter ac-
tivity. In cells expressing EGFP, rBDNF promoter IV lost all of its
induction when CRE element was mutated, as promoter induc-
tion decreased from 2.7-fold to 1.2-fold (p 	 0.0317) after
4 h, and from 3.1-fold to 0.84-fold (p 	 0.0016) after 8 h of
BDNF treatment. Similarly, in cells overexpressing A-CREB, the
mutation in CRE site decreased the induction of rBDNF pro-
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Figure 9. The CRTC family does not participate in the induction of BDNF transcripts after BDNF-TrkB signaling. Primary neurons were transduced at 0 DIV with lentiviral particles encoding EGFP,
as control, or CRTC dominant-negative protein (CRTC D-N). A, Transduced neurons were transfected with CRE-reporter at 6 DIV, and luciferase reporter activity was measured at 8 DIV after BDNF
treatment for the time indicated (n 	 4). Luciferase activity in cells transduced with EGFP-encoding lentiviral particles and not treated with BDNF was set as 1. B, At 8 DIV, transduced neurons were
treated with 50 ng/ml BDNF for the time indicated, and the levels of total BDNF (BDNF coding) and different BDNF transcripts were measured using qRT-PCR. The expression level of respective
transcripts in cells expressing EGFP not treated with BDNF was set as 1. Average of 3 independent experiments (n 	 3) is shown. Statistical significance between respective transcript levels in EGFP
and CRTC D-N-expressing cells at respective time points: no statistically significant results (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak method). Error bars indicate
SEM.
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from 2.3-fold to 1.4-fold (p 	 0.0420) after 8 h of BDNF
treatment.
Collectively, our results show that CREB family proteins and
the described CRE element in the BDNF promoter I region does
not contribute significantly to the activation of the promoter
after BDNF-TrkB signaling. In contrast, the induction of BDNF
promoter IV activity after BDNF-TrkB signaling is mainly medi-
ated by CREB family transcription factors through the CRE site in
the promoter region.
TrkB signaling-dependent regulation of BDNF promoters I
and IV, but not promoter IXa, by CREB family proteins is
partially conserved between rat and human
Functional CRE elements, which participate in neuronal activity-
dependent induction of the respective promoter activity, have
been described in human BDNF promoters I, IV, and IXa
(Pruunsild et al., 2011). We next decided to investigate whether
the role of CREB family transcription factors in the induction of
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Figure 10. CREB family transcription factors are involved in the activation of rat BDNF promoters I and IV after BDNF-TrkB signaling. Primary neurons were transfected at 6 DIV with different rat
BDNF promoter constructs or CRE reporter (CRE rep) together with EGFP or A-CREB overexpression constructs (A) or with wild-type (WT) rat BDNF promoter (rBDNF p) constructs and respective rat
BDNF promoter constructs with mutated CRE site (CREm) together with EGFP or A-CREB overexpression constructs (B) as shown below the graph. At 7 DIV, neurons were treated with 50 ng/ml BDNF
for 4 h (n 	 3) or 8 h (n 	 4) (A) and for 4 h (n 	 3) or 8 h (n 	 3) (B) or left untreated, and promoter activity was measured using luciferase reporter assay. Promoter activity was calculated relative
to the respective promoter activity in cells transfected with EGFP and not treated with BDNF (A) or as fold induction relative to the respective promoter activity in untreated cells transfected with EGFP
or A-CREB, respectively (B). Average of three or four independent experiments (n 	 3 or 4) is shown. Error bars indicate SEM. Statistical significance between the activity of respective promoter
regions in EGFP and A-CREB-overexpressing cells at respective time points (A) or between the induction of respective WT and CREm promoter regions in cells overexpressing EGFP or A-CREB,
respectively, at respective time points (B). **p 
 0.01; *p 
 0.05 (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak method).
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signaling is similar between rat and human. For that, we used
luciferase reporter assay with reporter constructs containing hu-
man or rat respective promoter regions (Fig. 11).
While the core CRE element in BDNF promoter I is conserved
between rodents and human, its flanking region differs (Fig.
11A). Therefore, we first investigated the regulation of rat and
human BDNF promoter I 5 region in response to BDNF-TrkB
signaling (Fig. 11D). Overexpression of A-CREB reduced the
TrkB signaling-dependent activation of both rat and human
BDNF promoter I 5. Notably, the effect of A-CREB was more
prominent on the activation of human BDNF promoter I 5, in
which case the activity of the promoter region decreased from
15-fold to 8.7-fold (p 	 0.0165) after 4 h, and from 26-fold
to 12-fold (p 	 0.0004) after 8 h BDNF-TrkB signaling. In
addition, we found that mutating the CRE site in the promoter I
5 only slightly decreased the TrkB-induced levels of promoter
activity of both human and rat BDNF promoter region (Fig. 11E).
Together, our data show that the activation of human BDNF
promoter I in response to BDNF-TrkB signaling is slightly more
dependent on CREB family transcription factors than the rat
ortholog, but not via CRE element located in the proximal
promoter.
Next, we examined the regulation of BDNF promoter IV. The
well-described CRE element in BDNF promoter IV has a murine
yt ivi tca esare ficu l e vi tale
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Figure 11. Regulation of BDNF promoters I and IV, but not promoter IXa, via CREB family after BDNF-TrkB signaling is partially conserved between rodents and humans. A–C, Graphical
representation of the conservation of previously described CRE elements in BDNF promoters I, IV, and IXa. Light blue shading represents the core sequence of the CRE element. D–I, Primary neurons
were transfected at 6 DIV with different rat and human BDNF promoter constructs (denoted as rBDNF and hBDNF, respectively) together with EGFP or A-CREB overexpression constructs (D, F, H ) or
with wild-type (WT) BDNF promoter construct or respective CRE-mutated promoter constructs (E, G, I ) as shown below the graph. At 7 DIV, neurons were treated with 50 ng/ml BDNF for different
time periods or left untreated as indicated, and promoter activity was measured using luciferase reporter assay. Promoter activity was calculated relative to the respective promoter activity in cells
transfected with EGFP and not treated with BDNF (D, F, H ) or as fold induction relative to the respective promoter activity in untreated cells (E, G, I ). Average of three or four independent experiments
(D, F, H: n 	 4; E, G, I: n 	 3) is shown. Error bars indicate SEM. Statistical significance between the inductions of respective promoter constructs in EGFP and A-CREB-overexpressing cells at
respective time points: ***p 
 0.001; **p 
 0.01; *p 
 0.05 (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak method).
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linage-specific single nucleotide difference between rat and hu-
man (GCACGTCA vs TCACGTCA; Fig. 11B), which could affect
CREB family-dependent regulation of the promoter activity.
Overexpression of A-CREB reduced the basal activity of both rat
and human BDNF promoter IV 1.3-fold (p 	 0.0100) and
1.5-fold (p 	 0.0793), respectively (Fig. 11F). Interestingly, rat
BDNF promoter IV was more inducible than the human or-
tholog, as both at 4 and 8 h of BDNF treatment the induction of
rat BDNF promoter IV activity in EGFP-expressing cells was
1.5-fold higher than its human counterpart. After BDNF-TrkB
signaling, the overexpression of A-CREB greatly reduced the ac-
tivity of rat BDNF promoter IV at all time points (Fig. 11F)
similarly to the previous experiment (Fig. 10A). Likewise, al-
though with a smaller effect, the activation of human BDNF pro-
moter IV in response to BDNF-TrkB signaling was reduced from
1.2-fold to 0.78-fold (p 	 0.0103) after 2 h, from 1.6-fold
to 1.2-fold (p 	 0.0295) after 4 h, and from 1.9-fold to 1.7-
fold (p 	 0.3809) after 8 h BDNF treatment by A-CREB
overexpression.
To determine whether the difference in the activation of rat
and human BDNF promoter IV results from the single-
nucleotide difference in the CRE element, we made reporter
constructs where we introduced human CRE element into rat
BDNF promoter region and rat CRE element into human
BDNF promoter region (Fig. 11G). We found that the single
nucleotide variation in the CRE element did not significantly
contribute to the difference in the inducibility of the promoter
IV region. We also determined that mutating the CRE element
in both rat and human BDNF promoter IV completely abol-
ished the induction of the promoter in response to BDNF-
TrkB signaling. Collectively, stronger activation of BDNF
promoter IV in response to BDNF-TrkB signaling seems to be
mediated by CREB family transcription factors, but the differ-
ence in the activation of rat and human respective promoters
is not due to the single nucleotide difference in the CRE
element.
In human BDNF promoter IXa, a functional CRE element
responsible for neuronal activity-dependent induction of the
promoter has been described (Pruunsild et al., 2011). However,
there is a 2 nucleotide difference in the CRE element between rat
and human (TGACGGCG vs TGACAGCA; Fig. 11C). We stud-
ied the induction of BDNF promoter IXa, and we found that
while the rat promoter IXa region is not inducible in response to
BDNF-TrkB signaling, the respective human promoter region is,
with up to 2.3-fold increase in the promoter activity after 8 h of
BDNF treatment (Fig. 11H). Notably, overexpression of A-CREB
decreased TrkB signaling-induced activity of the human BDNF
promoter IXa by 1.2-fold to 1.4-fold. We next localized the
regulatory elements required for the induction of the human
BDNF promoter IXa to the 112 bp 3 region of the promoter,
which showed similar activation in response to BDNF-TrkB sig-
naling as the full-length 908 bp promoter region (Fig. 11I). Re-
markably, mutating the CRE element completely abolished the
activation of the promoter, indicating that the CRE element is the
main mediator of TrkB signaling-dependent activation of human
BDNF promoter IXa. Collectively, we found remarkable differ-
ences in the regulation of BDNF promoter IXa between rat and
human, as the activity of the rat BDNF promoter IXa is not in-
ducible in response to BDNF-TrkB signaling, whereas the activity
of the human ortholog is through a primate lineage-specific CRE
element.
CREB transcription factor mediates the early induction of
exon IIc-, IV-, VI-, and IXa-containing BDNF transcripts after
BDNF-TrkB signaling
Our results with overexpression of A-CREB and treatment with
CCII indicated that CREB family is involved in the BDNF tran-
scriptional autoregulation, but neither of the experiments was
specific to CREB. Since the dimerization of A-CREB is based on
CREB leucine zipper domain, it can form dimers with the tran-
scription factors that also dimerize with CREB (e.g., possibly with
all the members of the CREB family). Also, CBP/p300 can inter-
act with several transcription factors via KIX domain. Therefore,
we next wanted to determine the role of CREB in BDNF tran-
scriptional autoregulation. We suppressed CREB1 mRNA ex-
pression using CRISPR interference, treated neurons with BDNF
at 8 DIV, and used qRT-PCR to measure the expression levels of
BDNF transcripts (Fig. 12).
First, we determined the efficiency of CREB1 knockdown in
our cultured neurons (Fig. 12A). We found that dCas9-KRAB
targeted to the CREB1 promoter region reduced CREB1 mRNA
levels 4.5-fold (p 	 0.00005) (Fig. 12A), which also reflected in
significant reduction of CREB protein level (data not shown).
Next, we studied the influence of CREB knockdown on BDNF
transcriptional autoregulation. Interestingly, suppressing CREB1
expression abolished the early induction of total BDNF expres-
sion levels, as after 1 h of BDNF-TrkB signaling, the induced
levels of total BDNF mRNA reduced from 2.9-fold to 1.2-fold
(p 	 0.0001) in CREB1 knockdown cells. After 3 h of BDNF
treatment, the induction of total BDNF mRNA decreased from
11-fold to 9-fold (p 	 0.0003), but no difference in the in-
duced levels was observed after 6 h of BDNF treatment. The
induced levels of BDNF transcripts containing exons I and III
were not significantly affected by the knockdown of CREB1. In
contrast, CREB knockdown reduced the induced levels of BDNF
transcripts containing exon IV and IXa from 5.5-fold to 1.5-
fold (p 	 0.0002) and from 8-fold to 3.6-fold (p 	 0.0035),
respectively, after 1 h of BDNF treatment. Also, CREB1 knock-
down reduced the induced levels of BDNF transcripts containing
exon IV from 13-fold to 7.7-fold (p 	 0.00008) after 3 h of
BDNF treatment. Furthermore, CREB1 knockdown also slightly
decreased the induced levels of exon IIc- and VI-containing
BDNF transcripts after 1 h of BDNF treatment: from 1.4-fold to
1.0-fold (p 	 0.0007) and from 1.8-fold to 1.4-fold (p 	
0.0013), respectively. Interestingly, we also observed a slight
1.3-fold upregulation of the basal expression level of both exon
III- and exon VI-containing BDNF transcripts (p 	 0.0256 and
p 	 0.0327, respectively). Together, our results show that CREB
transcription factor is required for the early induction of exon
IIc-, IV-, VI-, and IXa-containing BDNF transcripts, but only for
the later induction of exon IV-containing BDNF transcripts after
BDNF-TrkB signaling.
In contrast to the specific effect of CREB1 knockdown on
BDNF exon IV-containing transcripts and only on the early in-
duction of exon IIc, VI-, and IXa-containing transcripts, our re-
sults obtained with overexpression of A-CREB (Figs. 2, 3), and
using CCII and E1A overexpression (Figs. 5, 6) indicated the
involvement of CREB family in the regulation of most BDNF
transcripts at 3 h BDNF treatment. Notably, it has been shown
that the transcription factors within CREB family can compen-
sate for each other (Hummler et al., 1994; Mantamadiotis et al.,
2002; Díaz-Ruiz et al., 2008; Lemberger et al., 2008; Aguado et al.,
2009; Gundersen et al., 2013), so it is possible that other CREB
family members could have rescued the BDNF induction in
CREB1 knockdown neurons. Therefore, to investigate how
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BDNF-TrkB signaling and suppressing CREB1 levels influence
the expression of ATF1 and CREM, we measured their mRNA
levels using qRT-PCR (Fig. 12B).
We found that ATF1 was slightly induced in response to
BDNF-TrkB signaling with maximal induction of 1.5-fold after
6 h of BDNF treatment (Fig. 12B). Total CREM mRNA levels
peaked at 10-fold induction after 3 h of BDNF-TrkB signaling
(Fig. 12B). In response to CREB1 knockdown, the expression of
ATF1 mRNA did not change remarkably. However, the basal
level of total CREM mRNA was 5.2-fold (p 	 2  106) higher
in CREB knockdown neurons. Due to alternative splicing, the
CREM gene produces several CREM protein isoforms, which can
be transcriptional activators or repressors (Foulkes et al., 1991;
Laoide et al., 1993). For example, ICER is a repressive CREM
isoform that competes with CREB and provides a mechanism for
downregulation of cAMP-dependent gene expression (Molina et
al., 1993; Walker et al., 1998; Mioduszewska et al., 2003). To
measure the levels of CREM activator forms, we used primers
specific for CREM transcripts that contain KID domain-
encoding sequence (denoted as CREM with KID in Fig. 12B) and
observed moderate induction in response to BDNF-TrkB signal-
ing, peaking at 2.7-fold induction after 6 h of BDNF treatment.
We also saw 8.1-fold (p 	 0.00002) increase in the CREM
activator form mRNA levels in untreated CREB knockdown cells
(Fig. 12B).
As CREB1 knockdown greatly induced the expression of
CREM activator forms, it is possible that the discrepancy between
the results obtained with CREB1 knockdown and with A-CREB
and E1A overexpression and CCII treatment could originate
from CREM activator forms binding to CRE sites and thus regu-
lating CRE-dependent transcription in cells where CREB1 is
knocked down. Therefore, we next decided to elucidate the role
of CREM in BDNF transcriptional autoregulation. For that, we
knocked down the expression of CREM using CRISPR interfer-
ence (Fig. 13). We determined that CREM mRNA expression






























































































































































































































































Figure 12. CREB is necessary for the early induction of exon IIc, IV-, VI-, and IXa-containing BDNF transcripts after BDNF-TrkB signaling. Primary neurons were transduced at 0 DIV with lentiviral
particles coding for dCas9-KRAB, and CREB1 gRNA or negative gRNA (neg gRNA). At 8 DIV, neurons were treated with 50 ng/ml BDNF for the indicated time periods. Expression levels of CREB1, total
BDNF (BDNF coding), different BDNF transcripts (A) and other CREB family members (B) were measured using qRT-PCR. The expression level of respective transcripts in cells transduced with
dCas9-KRAB and negative gRNA-encoding lentiviral particles and not treated with BDNF was set as 1. Average of six independent experiments (n 	 6) is shown. Error bars indicate SEM. Statistical
significance between the respective transcript levels in cells overexpressing negative gRNA and CREB1 gRNA at respective time points: ***p 
0.001; **p 
0.01; *p 
0.05 (paired two-tailed t test,
corrected for multiple comparisons using Holm–Sidak method).
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level of CREB1 and ATF1 did not change in response to CREM
knockdown (Fig. 13A). Our data also showed that the induction
of BDNF transcripts was not affected by CREM knockdown (Fig.
13B).
Finally, we investigated possible compensatory mechanisms
between CREB and CREM by suppressing the expression of both
CREB1 and CREM simultaneously. If CREM really compensated
for CREB in BDNF autoregulation after CREB1 knockdown, one
should observe a stronger effect on BDNF autoregulation in cells
where both CREB1 and CREM are knocked down. In contrast, we
observed similar results as was seen with only CREB1 knock-
down; and no additional effect of CREM knockdown on BDNF
gene expression after BDNF-TrkB signaling was detected (data
not shown), indicating that CREM does not have compensatory
effect on BDNF autoregulation in CREB1 knockdown cells. To-
gether, our data show that, while CREM does not participate in
BDNF transcriptional autoregulation, CREB is indispensable for
the early induction of BDNF exon IIc, IV-, VI-, and IXa-
containing transcripts after BDNF-TrkB signaling.
Phosphorylated CREB binds to BDNF promoter IV after
BDNF-TrkB signaling and recruits CBP
To determine whether CREB directly binds rat BDNF promoters
in our cultured neurons and whether CREB binding changes after
BDNF-TrkB signaling, we treated neurons with BDNF for 1 h and
performed ChIP analysis with CREB and P-CREB antibodies. We
then determined promoter enrichment using qPCR (Fig. 14).
As a positive control for CREB binding, we used c-Fos pro-
moter, which showed 0.31% (p 	 0.0130) and 0.16% (p 	
0.0172) of input enrichment in untreated and BDNF-treated
cells, respectively (Fig. 11A). Rat BDNF promoters I, II, III, and
IXa showed no remarkable CREB binding compared with the
negative control rat BDNF 3 untranslated region. CREB binding
to rat BDNF promoter IV showed 0.025% (p 	 0.2223, uncor-
rected p 	 0.0410) of input enrichment in nontreated cells, and
0.022% (p 	 0.2467, uncorrected p 	 0.0461) of input enrich-
ment in BDNF-treated cells. Slight 0.019% (p 	 0.4438, uncor-
rected p 	 0.1364) and 0.015% of input enrichment (p 	 0.3647,



















































































































































































































Figure 13. CREM is not involved in the induction of BDNF transcripts after BDNF-TrkB signaling. Primary neurons were transduced at 0 DIV with lentiviral particles coding for dCas9-KRAB and a
combination of two CREM gRNAs or negative gRNA (neg gRNA). At 8 DIV, neurons were treated with 50 ng/ml BDNF for the indicated time periods. Expression levels of CREM with KID domain, CREB1
and ATF1 (A), and total BDNF (BDNF coding) and different BDNF transcripts (B) were measured using qRT-PCR. The expression level of respective transcripts in cells transduced with dCas9-KRAB and
negative gRNA-encoding lentiviral particles and not treated with BDNF was set as 1. Average of five independent experiments (n 	 5) is shown. Error bars indicate SEM. Statistical significance
between the respective transcript levels in cells overexpressing negative gRNA and CREM gRNAs at respective time points: **p 
 0.01 (paired two-tailed t test, corrected for multiple comparisons
using Holm–Sidak method).
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promoter VI in untreated cells and after BDNF treatment,
respectively.
Since we already established that CREB is phosphorylated af-
ter TrkB signaling (Fig. 4) we also investigated the binding of
phospho-Ser-133 CREB using ChIP analysis (Fig. 14B). In un-
treated and BDNF-treated neurons, we observed 0.31% (p 	
0.2553) and 0.97% (p 	 0.0063) of input enrichment, respec-
tively, at c-Fos promoter region for phospho-CREB. No remark-
able binding of phospho-CREB was detected to rat BDNF
promoters in nontreated cells. However, in response to BDNF-
TrkB signaling, phospho-CREB binding increased 3-fold to
4-fold at every region measured, including at the negative con-
trol region. As we did not detect CREB binding to rat BDNF
promoters I, II, III, and IXa, it is plausible that the observed
increase in phospho-CREB binding to these promoters in BDNF-
treated cells was an artifact due to overall higher phospho-CREB
protein levels in neurons, and not a functional recruitment of
phospho-CREB. In contrast, in BDNF-treated neurons, phospho-
CREB binding showed notable 0.13% (p 	 0.1333, uncorrected
p 	 0.0339) and 0.09% (p 	 0.1392, uncorrected p 	 0.0787) of
input enrichment at rat BDNF promoters IV and VI, respectively.
Together, our results indicate that CREB binds to BDNF pro-
Figure 14. CREB binds to BDNF promoter IV, is phosphorylated after BDNF-TrkB signaling, and recruits CBP. Primary neurons were treated at 7 DIV with 50 ng/ml BDNF for 1 h or left untreated
(CTRL) and then subjected to ChIP assay using CREB (A), phospho-Ser-133 CREB (P-CREB) (B), or CBP (C) antibodies (ab). DNA enrichment of c-Fos promoter, different rat BDNF (rBDNF ) promoter (p)
regions, and rat BDNF 3 untranslated region (rBDNF 3 UTR) was measured using qPCR. DNA enrichment is represented as percentage of input. Average of three or four (A, C, n 	 4; B, n 	 3)
independent experiments is shown. Error bars indicate SEM. No antibody controls depict the same dataset in A and B. Statistical significance is relative to the enrichment of rBDNF 3 UTR region in
respectively treated cells. Statistical analysis was not performed on no antibody controls. **p 
 0.01; *p 
 0.05 (paired two-tailed t test, corrected for multiple comparisons using Holm–Sidak
method).
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moter IV and the binding of phosphorylated CREB increases
after BDNF-TrkB signaling.
To clarify whether the requirement for CBP/p300 (Figs. 5, 6) is
because of direct binding of CBP to BDNF proximal promoters,
we also performed CBP ChIP with an antibody that does not
cross-react with p300 and measured CBP binding to BDNF pro-
moters with qPCR (Fig. 14C). We determined that CBP enrich-
ment at c-Fos promoter was 0.10% (p 	 0.0354) of input in
untreated neurons and 0.47% (p 	 0.0377) of input in BDNF-
treated neurons. In untreated cells, CBP was not remarkably en-
riched at BDNF promoter regions compared with the enrichment
at the negative control region BDNF 3 UTR. However, after
BDNF treatment we saw CBP binding to BDNF promoters I, III,
and IV, and possibly to promoter VI, showing 0.18% (p 	
0.0377), 0.14% (p 	 0.0377), 0.25% (p 	 0.0343), and
0.15% (p 	 0.0587, uncorrected p 	 0.0199) of input enrich-
ment, respectively. Since we did not detect such extensive binding
of P-CREB to BDNF promoters I and III (and possibly VI), it is
plausible that CBP is recruited to these BDNF promoters via
transcription factors other than CREB. Collectively, our results
show that CREB binds to BDNF promoter IV, is phosphorylated
after BDNF-TrkB signaling, and recruits CBP to increase BDNF
expression.
All BDNF transcripts are induced in the adult rat
hippocampus in vivo after BDNF-TrkB signaling
It has previously been shown that brief infusion of BDNF protein
into adult rat hippocampus results in transcription-dependent
LTP (Messaoudi et al., 2002), which requires MAPK pathway
activation leading to CREB phosphorylation (Ying et al., 2002).
Furthermore, infusion of BDNF into rat hippocampus induces
the expression of BDNF exon IV-containing transcripts (Wibrand et
al., 2006), whereas the expression of other BDNF transcripts has
not been studied. To determine whether the BDNF transcrip-
tional autoregulation pattern we have described here in cultured
neurons is also present in vivo, we infused BDNF protein into
adult rat hippocampus to elicit BDNF-LTP and measured the
expression levels of different BDNF transcripts in the dentate
gyrus region of the hippocampus using qRT-PCR (Fig. 15).
Local infusion of BDNF but not CytC into dentate gyrus elic-
ited an 30% increase in the fEPSP slope (Fig. 15A), indicating




































































































































































































































Figure 15. BDNF infusion into rat hippocampus elicits enhanced synaptic transmission and induces the expression of all BDNF transcripts in the hippocampal dentate gyrus region. A, Time course
plots of fEPSP slope recorded before and after BDNF or CytC infusion (left) and sample field potential traces (right). A total of 2 l (1 g/l) of BDNF or CytC was infused over 25 min into the dentate
gyrus over the period indicated by the gray bar. The evoked fEPSP slope change is expressed in percentage of baseline. Depicted values are mean  SEM of 6 independent animals (n 	 6 for both
groups). B, The expression levels of different BDNF transcripts was measured from dentate gyri of both ipsilateral and contralateral hemisphere using qRT-PCR. The expression levels of BDNF
transcripts were normalized to the HPRT1 expression levels and are depicted as fold induction compared with the respective transcript expression levels in the contralateral hemisphere. Dots
represent data from all the experiments. Horizontal line indicates the geometric mean of 5 or 6 independent animals (n 	 5 or 6). Dashed line indicates the level of respective transcripts in the
contralateral side and was set as 1 (no induction). Statistical significance between the respective transcript levels in dentate gyri of ipsilateral and contralateral hemispheres: ***p 
 0.001 (paired
two-tailed t test, corrected for multiple comparisons using Holm–Sidak method).
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infused with CytC, we did not detect induction of any BDNF
transcripts 2 h after the infusion (Fig. 15). Likewise, 30 min after
BDNF infusion, the expression levels of different BDNF tran-
scripts were similar to the expression levels in the contralateral
hemisphere. Notably, 2 h after the infusion of BDNF protein, the
expression of all the BDNF transcripts was induced. Total BDNF
mRNA level increased 9.3-fold (p 	 5  107), and the stron-
gest inductions were seen for BDNF exon IV- and IXa-containing
transcripts, which were induced 33.3-fold (p 	 6106) and
22.4-fold (p 	 4  105), respectively, after 2 h of BDNF
infusion. Moderate induction of 8.8-fold (p 	 9  105) and
5.6-fold (p 	 7  108) was seen for BDNF exon I- and VI-
containing transcripts, respectively, and exon IIc- and III-
containing BDNF transcripts showed slight but statistically
significant 3.8-fold (p 	 9  106) and 2.3-fold (p 	 3 
106) induction, respectively. Collectively, our results indicate
that extensive BDNF transcriptional autoregulatory loop also oc-
curs in vivo, encompassing all the major BDNF transcripts.
Discussion
The early induction of total BDNF mRNA levels in response to
neuronal activity has been shown to be independent of protein
synthesis (Hughes et al., 1993; Castrén et al., 1998). Additionally,
the neuronal activity-dependent induction of BDNF exon IV-
containing transcripts has been shown to be protein synthesis-
independent (Lauterborn et al., 1996; Tao et al., 1998), while the
induction of BDNF transcripts containing exon I and II depends
on protein synthesis (Lauterborn et al., 1996). Here, we have
determined the requirement for protein synthesis in BDNF tran-
scriptional autoregulation. Our results show that the induction of
most BDNF transcripts upon BDNF-TrkB signaling depends on
protein synthesis, and only the early induction of BDNF exon
IIc-, IV-, and VI-containing transcripts is partially protein
synthesis-independent. The de novo protein synthesis-inde-
pendent early induction of these BDNF transcripts could be ex-
plained by their regulation via CREB family proteins that are
constitutively expressed and whose activity is regulated through
post-translational mechanisms (for review, see Johannessen et
al., 2004). Notably, the requirement for protein synthesis suggests
that, in addition to constitutively expressed proteins, inducible
transcription factors are necessary for the BDNF transcriptional
autoregulation. For example, we have previously shown that
AP-1 transcription factors regulate BDNF gene expression after
TrkB signaling (Tuvikene et al., 2016).
It is well known that CREB transcription factor family regu-
lates the transcription of BDNF, especially the activation of BDNF
promoter IV (Shieh et al., 1998; Tao et al., 1998; Cha-Molstad et
al., 2004; Hong et al., 2008; Pruunsild et al., 2011; West et al.,
2014), but also BDNF promoter I (Tabuchi et al., 2002; Benito et
al., 2011) in response to neuronal activity. Here, we have discov-
ered that the CREB family is also a major regulator of BDNF gene
expression after TrkB signaling. We show that USF and NFAT
transcription factor families, which have previously been shown
to be involved in neuronal activity-regulated BDNF gene expres-
sion (Chen et al., 2003; Vashishta et al., 2009; Pruunsild et al.,
2011), do not significantly contribute to BDNF gene induction
after TrkB signaling. This implies that the mechanisms of BDNF
gene expression triggered by BDNF-TrkB signaling and neu-
ronal activity differ. Notably, none of the dominant-negative
proteins we used in our experiments completely abolished the
induction of BDNF transcription after TrkB signaling, indicat-
ing that there are other, yet to be determined transcription
factors involved in the BDNF autoregulation. Considering the
profound effect of A-CREB overexpression on the expression
of all major BDNF transcripts, one could hypothesize that
important de novo synthesized transcription factors regulating
BDNF gene expression are indeed CREB target genes. It is also
plausible that CREB acts as a nucleating factor for other, de
novo synthesized transcription factors to bind the BDNF pro-
moters, as it has been proposed for BDNF promoter IV (Hong
et al., 2008).
It is important to note the possible TrkB signaling-dependent
component in the regulation of BDNF gene expression in para-
digms using membrane depolarization. It has been described that
neuronal activity induces BDNF secretion (for review, see Park
and Poo, 2013), which could consequently activate TrkB recep-
tors, possibly giving rise to the BDNF-TrkB autoregulatory loop.
In the light of our results, it is plausible that neuronal activity
induces BDNF expression and the subsequent BDNF-TrkB sig-
naling maintains the expression of BDNF via an autonomous
pathway. For example, the impairment of BDNF induction after
kainic acid infusion in TrkB.T1 overexpressing mice implies that
BDNF-TrkB signaling is required for proper BDNF expression in
the brain after neuronal activity (Saarelainen et al., 2001).
It has been reported that CREB-mediated regulation of gene
expression plays an important role in the proper development of
the nervous system and neurons (Lonze and Ginty, 2002). There-
fore, the effect of overexpressing dominan-negative CREB family
protein, A-CREB, on the development and maturation of neu-
rons in culture is an important question that should be kept in
mind when interpreting our results. Results of our experiments
with long-term overexpression of A-CREB are in good accor-
dance with the results of our experiments with acute treatment of
CREB-CBP interaction inhibitor (CCII), supporting the notion
that CREB family regulates BDNF transcriptional autoregulation
independent of potential developmental changes. Our results
also showed the requirement for CREB family and its interaction
with CBP/p300 for the early induction of BDNF gene after TrkB
signaling. Notably, at a later phase, after 6 h of BDNF treatment,
neither A-CREB nor CCII had an influence on BDNF gene induc-
tion. Furthermore, knockdown of CREB1 expression also af-
fected only the early induction of BDNF exon IIc-, IV-, VI-, and
IXa-containing transcripts. This indicates that, while the early
phase of TrkB signaling-dependent induction of BDNF in neu-
rons is regulated by CREB-CBP/p300 complex, the late phase of
induction is regulated in a CREB family-independent manner. In
contrast, inhibition of CBP/p300 by overexpressing E1A strongly
decreased both the early and late phase of BDNF gene induction
after TrkB signaling. This could be explained by the fact that
numerous other transcription factors in addition to CREB family
proteins recruit CBP/p300 to regulate gene expression (Bedford
et al., 2010). Furthermore, while we only noted CREB binding to
BDNF promoter IV and possibly VI, we saw CBP binding to
various BDNF promoters: promoter I, III, IV, and possibly VI.
This further suggests that, while CREB recruits CBP to BDNF
promoter IV and possibly to promoter VI, other transcription
factors recruit CBP to other BDNF promoters.
The CREB family has been associated with the regulation of
BDNF in both rodents and humans. Here, we found that, al-
though the general activation of BDNF promoters I and IV in
response to BDNF-TrkB signaling was conserved between hu-
man and rat, subtle differences existed in their regulation by
CREB family proteins. The activation of human BDNF promoter
I was slightly more dependent on CREB family transcription fac-
tors than the rat ortholog. Furthermore, we found that the hu-
man BDNF promoter IV region was less inducible than the
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respective rat counterpart, and our results indicate potential
CREB family-dependent differences in the regulation of this pro-
moter between rat and human. It is notable that the murine-
specific single nucleotide difference, which is absent in other
major mammalian clades in BDNF promoter IV CRE element,
does not remarkably change the activity of the promoter in cul-
tured rat neurons. On the contrary, the two-nucleotide difference
in the CRE element between human and rat BDNF promoter IXa
seems to be responsible for the BDNF-TrkB signaling-dependent
activation of human promoter, which is absent for the rat or-
tholog. As we have found a profound difference in the regulation
of BDNF promoter IXa region in rat and human, the regulation
of the human BDNF promoter IXa after BDNF-TrkB signaling in
the endogenous context will need to be clarified in future
research.
Importantly, our data suggest the existence of distal enhancer
elements for BDNF gene regulation after TrkB signaling. First,
overexpression of A-CREB did not decrease the induction from
BDNF proximal promoters II, III, and VI in promoter assays,
whereas overexpression of A-CREB reduced the induction of all
these BDNF transcripts in the endogenous context. Second, the
expression of rat endogenous BDNF exon IXa-containing tran-
scripts is induced rapidly in response to BDNF-TrkB signaling,
whereas the BDNF proximal promoter IXa was not inducible in
our promoter activity assays. Third, functional CRE elements in
rodents have only been described in BDNF promoters I and IV,
and we also discovered that the CRE element in BDNF promoter
IV was necessary for the activation of the proximal promoter
region. On the contrary, our results using overexpression of
A-CREB, treatment with CCII, and overexpression of E1A
showed a strong effect on the induction of all the investigated
BDNF transcripts. Moreover, CBP has been widely associated
with enhancer regions (Kim et al., 2010). Notably, it has been
reported that the binding of CREB coactivator CRTC1 is prefer-
ential to promoters containing a TATA box (Parra-Damas et al.,
2017) for the interaction with general transcription factors
(Conkright et al., 2003). As we found in our work that neither
CRTC1 nor other CRTC family coactivators are required, while
CBP is necessary for the BDNF transcriptional autoregulation, it
could imply that BDNF gene expression is regulated by a distal
enhancer region, not only by the proximal promoter regions.
Together, these contradictions imply that important regulatory
areas responsible for BDNF-TrkB signaling-dependent BDNF in-
duction are located outside of the proximal promoter regions,
possibly even outside the BDNF gene. As we noted an effect on all
measured BDNF transcripts with A-CREB, CCII, and E1A, it is
plausible that there is a locus control region affecting the expres-
sion of the whole BDNF gene, and the cis-elements in proximal
promoter regions provide fine-tuning of the expression of differ-
ent BDNF transcripts in response to TrkB signaling.
Dysregulation of BDNF expression in a brain region and cell
type-specific manner has been implicated in various neurological
and neurodevelopmental disorders and in various neurodegen-
erative diseases (Zuccato and Cattaneo, 2009; Autry and Monteg-
gia, 2012; Tejeda and Díaz-Guerra, 2017). Although modulating
BDNF levels could be successful in therapy, the challenge lies in
controlling BDNF expression in a precise spatiotemporal man-
ner. It has been shown that uniform overexpression of BDNF in
the excitatory neurons of the forebrain, including hippocampus
and amygdala, causes anxiety-like behavior (Govindarajan et al.,
2006). Additionally, increased levels of BDNF protein in PFC and
hippocampus impairs working memory and fear conditioning,
increases susceptibility to seizures, and also causes an anxiety-like
phenotype (Papaleo et al., 2011). This has raised the need to
ultimately enhance the transcription of BDNF specifically in cells
that express BDNF under physiological conditions, to minimize
serious side effects. The knowledge of how BDNF promoters are
regulated in response to BDNF-TrkB signaling added by this
study could provide solutions to the challenges of precisely ad-
justing BDNF levels in both health and disease.
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Castrén E, Berninger B, Leingärtner A, Lindholm D (1998) Regulation of
brain-derived neurotrophic factor mRNA levels in hippocampus by neu-
ronal activity. Prog Brain Res 117:57– 64.
Cha-Molstad H, Keller DM, Yochum GS, Impey S, Goodman RH (2004)
Cell-type-specific binding of the transcription factor CREB to the cAMP-
response element. Proc Natl Acad Sci U S A 101:13572–13577.
Chen WG, West AE, Tao X, Corfas G, Szentirmay MN, Sawadogo M, Vinson
C, Greenberg ME (2003) Upstream stimulatory factors are mediators of
Ca 2-responsive transcription in neurons. J Neurosci 23:2572–2581.
Ch’ng TH, Uzgil B, Lin P, Avliyakulov NK, O’Dell TJ, Martin KC (2012)
Activity-dependent transport of the transcriptional coactivator CRTC1
from synapse to nucleus. Cell 150:207–221.
1424 • J. Neurosci., February 12, 2020 • 40(7):1405–1426 Esvald, Tuvikene et al. • CREB Family in BDNF Transcriptional Autoregulation
Conkright MD, Canettieri G, Screaton R, Guzman E, Miraglia L, Hogenesch
JB, Montminy M (2003) TORCs: transducers of regulated CREB activ-
ity. Mol Cell 12:413– 423.
Díaz-Ruiz C, Parlato R, Aguado F, Ureña JM, Burgaya F, Martínez A, Car-
mona MA, Kreiner G, Bleckmann S, Del Río JA, Schütz G, Soriano E
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